Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Nivolumab extends survival for NSCLC

Share :

2015 ASCO Annual Meeting
Published: 29 May 2015
Views: 3083
Rating:
Save
Prof Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain

Dr Luis Paz-Ares presents at ASCO 2015 data from a randomised phase III study that indicate PD-1 immunotherapy is an effective treatment option for patients with non-squamous, non-small cell lung cancer (NSCLC).

Read the news article and watch the interview.

Related Videos

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC

Dr Marina Garassino - University of Chicago, Chicago, USA
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )
26 Sep 2024

ESMO 2024: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2024: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )
16 Sep 2024

Immunotherapy resistance pathways investigated to tailor combination NSCLC therapy

Prof Pascale Tomasini - Aix-Marseille University, Marseille, France
Immunotherapy resistance pathways investigated to tailor combination NSCLC therapy ( Prof Pascale Tomasini - Aix-Marseille University, Marseille, France )
16 Sep 2024

Mutational-based treatment approach may significantly improve outcomes in pretreated patients with metastatic solid tumours

Dr Andrea Botticelli - Sapienza Università di Roma, Rome, Italy
Mutational-based treatment approach may significantly improve outcomes in pretreated patients with metastatic solid tumours ( Dr Andrea Botticelli - Sapienza Università di Roma, Rome, Italy )
16 Sep 2024

ESMO 2024: Latest in EGFR mutated NSCLC

Prof Ignacio Gil-Bazo, Dr Mariana Brandão, Prof Benjamin Besse and Prof Enriqueta Felip
ESMO 2024: Latest in EGFR mutated NSCLC ( Prof Ignacio Gil-Bazo, Dr Mariana Brandão, Prof Benjamin Besse and Prof Enriqueta Felip )
16 Sep 2024

Biomarkers, predictive and prognostic factors of resistance to immunotherapy

Dr Ignacio Gil-Bazo - Fundación Instituto Valenciano de Oncología (FIVO)/Clínica Universidad de Navarra, Spain
Biomarkers, predictive and prognostic factors of resistance to immunotherapy ( Dr Ignacio Gil-Bazo - Fundación Instituto Valenciano de Oncología (FIVO)/Clínica Universidad de Navarra, Spain )
12 Jul 2024

Uncommon genetic aberrations NTRK, RET, NRG

Dr Luis E. Raez - Memorial Cancer Institute, Miami, USA
Uncommon genetic aberrations NTRK, RET, NRG ( Dr Luis E. Raez - Memorial Cancer Institute, Miami, USA )
12 Jul 2024

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom
ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )
26 Jun 2024

ASCO 2024: Lung cancer roundup

Dr Luis Raez - Memorial Cancer Institute, Miami, USA
ASCO 2024: Lung cancer roundup ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )
4 Jun 2024

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation